Velomedix nets IDE to study hypothermia in acute MI patients

Justine Varieur Cadet | | Health Imaging | Screening
Velomedix, a clinical-stage medical device company, has received Investigational Device Exemption (IDE) approval from the FDA to evaluate the use of therapeutic hypothermia for the treatment of patients suffering an acute MI.

The conditional approval allows the company to initiate a clinical trial at select sites in the U.S. The IDE study will build upon limited data developed over the last eight years for the use of therapeutic hypothermia for MI patients, according to the Menlo Park, Calif.-based company.

It is anticipated the Velomedix IDE study will begin enrolling patients in the second half of 2012.

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.